Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma.

Gynecol Oncol

Gynecologic Oncology Department, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy.

Published: July 1998

Objective: The objective was to determine if maximal cytoreductive surgery could carry any benefit in pelvic and abdominal recurrent endometrial carcinoma.

Methods: Twenty women at their first large pelvic or abdominal recurrence from endometrial carcinoma were treated with maximal cytoreductive surgery. Women were classified as R1 (residual tumor) or R0 (no residual tumor) by tumor left at the end of surgery. Adjuvant postoperative therapy was undertaken upon clinical judgement. Progression-free, overall, and cancer-related survivals were analyzed with the product-limit method and compared with the log-rank test. The Cox regression model was used to study the variables involved in progression-free and overall survival.

Results: Complete macroscopic resection of tumor was feasible in 13 women (65%). R0 group women had a significant both progression-free (median reached at 9.1 months) and overall survival (median reached at 11.8 months) compared to R1 group women. There were 2 (10%) perioperative deaths. Eight women died of cancer, 5 in the R1 group and 3 in the R0 group. There were four intercurrent deaths in women still free from the disease. Local control of neoplasia was achieved in 84.6% of R0 women and their survival was affected mostly by distant recurrences or intercurrent deaths. Residual tumor at the end of surgery was the only significant variable to affect both progression-free and overall survival.

Conclusion: Intensive surgery is a valid treatment option in women with large pelvic or abdominal recurrence from endometrial carcinoma. Tumor can be completely resected and local control of the disease can be achieved in most of the patients, although survival could be affected by distant recurrence and intercurrent deaths.

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.1998.5017DOI Listing

Publication Analysis

Top Keywords

maximal cytoreductive
12
cytoreductive surgery
12
endometrial carcinoma
12
pelvic abdominal
12
residual tumor
12
intercurrent deaths
12
women
9
recurrent endometrial
8
women large
8
large pelvic
8

Similar Publications

Background And Objective: Krukenberg tumours (KTs) are metastatic signet ring cell (SRC) adenocarcinomas of the ovary, arising from the stomach in most cases (70%). Other common primary sites are the colon, appendix and breast. The use of the term "Krukenberg tumour" is inconsistent in the literature which makes data interpretation difficult.

View Article and Find Full Text PDF

Surgical Management of Neuroendocrine Tumor Liver Metastases.

Hematol Oncol Clin North Am

February 2025

Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA. Electronic address:

Patients with neuroendocrine tumor liver metastases (NETLMs) may develop carcinoid syndrome, carcinoid heart disease, or other symptoms from overproduction of hormones. Hepatic resection and cytoreduction is the most direct treatment of NETLMs in eligible patients, and cytoreduction improves symptoms, may reduce the sequelae of carcinoid syndrome, and extends survival. Parenchymal-sparing procedures, such as ablation and enucleation, should be considered during cytoreduction to maximize treatment of multifocal tumors while preserving healthy liver tissue.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the management of advanced ovarian cancer, highlighting the gold standard of complete removal of visible tumors, and exploring the implications of delayed cytoreductive surgery for patients who cannot undergo initial or interval surgery.
  • It is a retrospective analysis of patients with stage IIIC or higher ovarian cancer at the Northern Gynaecological Oncology Centre over six years, comparing survival outcomes between two groups: those who received only chemotherapy and those who had delayed surgery after six cycles.
  • Of the 89 patients evaluated, most completed six cycles of chemotherapy without surgery, while a smaller group underwent delayed surgery, suggesting a potential benefit from this approach in specific cases where initial surgery was not feasible.
View Article and Find Full Text PDF

Cytoreductive surgery (CRS) coupled with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative approach to peritoneal disease (PD) and corresponds to the needs of patients with dire survival rates. However, the oncological community remains cautious toward this procedure because of its significant morbidity and mortality rates. This evolving evidence around CRS and HIPEC and its impact suggests a need for more standardized procedures in existing centers.

View Article and Find Full Text PDF

There are several retrospective studies which have suggested that optimal cytoreductive surgery for stage IV endometrial cancer improves survival [1-3]. In addition, some investigators have reported that achieving maximal cytoreduction to a visibly disease-free outcome in the abdominal cavity for endometrial cancer with distant metastases can extend patients' survival [4]. Due to the anatomic proximity of the rectosigmoid colon to the female pelvic organs and its involvement in locally advanced endometrial cancer, an en bloc resection of the uterus, adnexa, and rectosigmoid, also known as a modified posterior pelvic exenteration (MPPE), is performed to achieve optimal cytoreduction [5,6].

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!